HomeCompareMLCT vs JNJ

MLCT vs JNJ: Dividend Comparison 2026

MLCT yields 1025.64% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLCT wins by $23506543.50M in total portfolio value
10 years
MLCT
MLCT
● Live price
1025.64%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23506543.53M
Annual income
$19,723,609,349,823.79
Full MLCT calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — MLCT vs JNJ

📍 MLCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLCTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLCT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLCT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLCT
Annual income on $10K today (after 15% tax)
$87,179.49/yr
After 10yr DRIP, annual income (after tax)
$16,765,067,947,350.22/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, MLCT beats the other by $16,765,067,943,312.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLCT + JNJ for your $10,000?

MLCT: 50%JNJ: 50%
100% JNJ50/50100% MLCT
Portfolio after 10yr
$11753271.78M
Annual income
$9,861,804,677,286.84/yr
Blended yield
83.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MLCT
No analyst data
Altman Z
-1.8
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLCT buys
0
JNJ buys
0
No recent congressional trades found for MLCT or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLCTJNJ
Forward yield1025.64%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$23506543.53M$30.5K
Annual income after 10y$19,723,609,349,823.79$4,749.88
Total dividends collected$23218513.75M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MLCT vs JNJ ($10,000, DRIP)

YearMLCT PortfolioMLCT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$113,264$102,564.10$10,594$274.49+$102.7KMLCT
2$1,206,878$1,085,685.14$11,294$360.69+$1.20MMLCT
3$12,102,987$10,811,628.23$12,133$476.91+$12.09MMLCT
4$114,279,868$101,329,670.98$13,156$635.42+$114.27MMLCT
5$1,016,469,856$894,190,397.43$14,432$854.61+$1016.46MMLCT
6$8,520,740,273$7,433,117,527.67$16,056$1,162.76+$8520.72MMLCT
7$67,350,310,269$58,233,118,176.66$18,175$1,604.53+$67350.29MMLCT
8$502,243,173,894$430,178,341,906.41$21,009$2,252.68+$502243.15MMLCT
9$3,535,452,502,858$2,998,052,306,790.74$24,911$3,229.73+$3535452.48MMLCT
10$23,506,543,527,881$19,723,609,349,823.79$30,458$4,749.88+$23506543.50MMLCT

MLCT vs JNJ: Complete Analysis 2026

MLCTStock

Malachite Innovations, Inc., together with its subsidiaries, provides health and wellness products in the United States. It offers a portfolio of approximately 100 novel cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. The company also develops THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. In addition, it engages in identifying, investing in, and repositioning environmental situations with a focus on technological innovations and eco-friendly solutions. The company was formerly known as Vitality Biopharma, Inc. and changed its name to Malachite Innovations, Inc. in October 2021. Malachite Innovations, Inc. was incorporated in 2007 and is headquartered in Cleveland, Ohio.

Full MLCT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MLCT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLCT vs SCHDMLCT vs JEPIMLCT vs OMLCT vs KOMLCT vs MAINMLCT vs ABBVMLCT vs MRKMLCT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.